NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel drug delivery for intracranial malignancies, including glioblastoma and brain metastases.

• Lead products are NEO100 (intranasal perillyl alcohol) and NEO212 (oral/intranasal temozolomide conjugate), both targeting brain cancers and other CNS diseases.

• NEO100 is in Phase IIa trials for glioma and meningioma; NEO212 has begun Phase I/II trials for brain tumors.

• Pipeline includes applications for pediatric brain tumors and Parkinson’s disease.

• No commercial products or sales infrastructure; revenue to date is minimal and from humanitarian use.

Financial performance and metrics

• Net loss of $11.9M in 2024 and $14.9M in 2023; accumulated deficit of $88.6M as of March 31, 2025.

• Revenue from January 2023 to March 2025 totaled $39,990; no significant product sales expected in the near future.

• Cash balance of $5.4M as of March 31, 2025; shareholders’ deficit of $9.6M.

• Significant operating expenses driven by R&D, legal, and share-based compensation.

• Auditor’s report includes a going concern warning due to recurring losses and need for additional funding.

Use of proceeds and capital allocation

• Proceeds from ELOC Financing with Mast Hill Fund, LP, up to $50M, to be used for general corporate purposes.

• Management has broad discretion over use of funds; may invest in R&D, clinical trials, and operational expenses.

• No proceeds from resale of shares by Mast Hill; company only receives funds from direct sales under the Equity Purchase Agreement.